Vorapaxar + Placebo
Phase 3Terminated 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerosis
Conditions
Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
Trial Timeline
Dec 1, 2007 โ Jul 1, 2011
NCT ID
NCT00527943About Vorapaxar + Placebo
Vorapaxar + Placebo is a phase 3 stage product being developed by Merck for Atherosclerosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00527943. Target conditions include Atherosclerosis, Myocardial Ischemia, Myocardial Infarction.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02394730 | Phase 1/2 | Completed |
| NCT00527943 | Phase 3 | Terminated |
| NCT00526474 | Phase 3 | Completed |
Competing Products
20 competing products in Atherosclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| Olmesartan medoxomil + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| Pactimibe sulfate | Daiichi Sankyo | Phase 2/3 | 65 |
| Pactimibe | Daiichi Sankyo | Phase 2 | 52 |
| Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin | Daiichi Sankyo | Phase 3 | 77 |
| Micronized 17B-estradiol | Johnson & Johnson | Phase 2/3 | 65 |
| Rosuvastatin + placebo + aspirin + placebo | AstraZeneca | Approved | 85 |
| Rosuvastatin + Placebo | AstraZeneca | Approved | 85 |
| rosuvastatin + placebo | AstraZeneca | Phase 1 | 33 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 1 | 33 |
| Rosuvastatin + Atorvastatin | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin (5mg๏ผ10mg๏ผ20mg) + Rosuvastatin 5mg | AstraZeneca | Approved | 85 |
| Vorapaxar + Placebo | Merck | Phase 3 | 77 |
| Vorapaxar + Placebo + Aspirin + Clopidogrel | Merck | Phase 2 | 52 |
| Niacin/simvastatin compared to simvastatin alone at 2 doses | Merck | Approved | 85 |
| lovastatin | Merck | Phase 2/3 | 65 |
| Ezetimibe + Placebo | Merck | Approved | 85 |
| Niaspan | Merck | Pre-clinical | 23 |
| MK0633 | Merck | Phase 2 | 52 |